scholarly journals 33 Association of the lupus low disease activity state (lldas) with health related quality of life

2017 ◽  
Author(s):  
V Golder ◽  
R Kandane-rathnayake ◽  
A Hoi ◽  
M Huq ◽  
W Louthrenoo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Disease Activity ◽  
Health Related Quality ◽  
Low Disease Activity ◽  
Related Quality ◽  
Health Related ◽  
Activity State

scholarly journals Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study

2017 ◽  
Vol 19 (1) ◽  
Author(s):  
Vera Golder ◽  
◽  
Rangi Kandane-Rathnayake ◽  
Alberta Yik-Bun Hoi ◽  
Molla Huq ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prospective Study ◽  
Disease Activity ◽  
Health Related Quality ◽  
Low Disease Activity ◽  
Related Quality ◽  
Health Related ◽  
Activity State

Better Health‐Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort

2020 ◽  
Vol 72 (8) ◽  
pp. 1159-1162 ◽  
Author(s):  
Manuel F. Ugarte‐Gil ◽  
Rocío V. Gamboa‐Cárdenas ◽  
Cristina Reátegui‐Sokolova ◽  
Mariela Medina‐Chinchón ◽  
Francisco Zevallos ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Health Related Quality ◽  
Systemic Lupus ◽  
Low Disease Activity ◽  
Related Quality ◽  
Health Related ◽  
Activity State

scholarly journals 175 Low disease activity state (LDAS) predicts a better health-related quality of life (HRQoL) in systemic lupus erythematosus (SLE) patients

2019 ◽  
Author(s):  
Manuel F Ugarte-Gil ◽  
Rocío Gamboa-Cárdenas ◽  
Cristina Reátegui-Sokolova ◽  
Mariela Medina-Chinchón ◽  
Francisco Zevallos ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Health Related Quality ◽  
Systemic Lupus ◽  
Low Disease Activity ◽  
Related Quality ◽  
Health Related ◽  
Activity State

scholarly journals CS-23 Remission and low disease activity state are associated with a better health-related quality of life in systemic lupus erythematosus in a primarily mestizo population

2018 ◽  
Author(s):  
Manuel F Ugarte-Gil ◽  
Rocio V Gamboa-Cardenas ◽  
Mariela Medina-Chinchón ◽  
Francisco Zevallos ◽  
Cristina Reátegui-Sokolova ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Health Related Quality ◽  
Systemic Lupus ◽  
Low Disease Activity ◽  
Related Quality ◽  
Health Related ◽  
Activity State

scholarly journals 115. The Remira Study: The Impact of Sustained Remission on Health-Related Quality of Life in Rheumatoid Arthritis Patients with Low Disease Activity State

Rheumatology ◽  
2014 ◽  
Vol 53 (suppl_1) ◽  
pp. i101-i101 ◽  
Author(s):  
Margaret H. Y. Ma ◽  
Fowzia Ibrahim ◽  
Gabrielle H. Kingsley ◽  
Andrew P. Cope ◽  
David L. Scott
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Sustained Remission ◽  
Health Related Quality ◽  
Low Disease Activity ◽  
Related Quality ◽  
Health Related ◽  
Activity State ◽  
The Impact

scholarly journals The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial

2021 ◽  
Author(s):  
Alexis Ogdie ◽  
Jessica A. Walsh ◽  
Soumya D. Chakravarty ◽  
Steven Peterson ◽  
Kim Hung Lo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Psoriatic Arthritis ◽  
Disease Activity ◽  
Productivity Loss ◽  
Health Related Quality ◽  
Functional Capability ◽  
Related Quality ◽  
Health Related ◽  
Eq Vas

Abstract Introduction/objectives To evaluate changes in health-related quality of life (HRQoL) and productivity following treatment with intravenous (IV) golimumab in patients with psoriatic arthritis (PsA). Methods Patients were randomized to IV golimumab 2 mg/kg (n=241) at Weeks 0, 4, then every 8 weeks (q8w) through Week 52 or placebo (n=239) at Weeks 0, 4, then q8w, with crossover to IV golimumab 2 mg/kg at Weeks 24, 28, then q8w through Week 52. Change from baseline in EuroQol-5 dimension-5 level (EQ-5D-5L) index and visual analog scale (EQ-VAS), daily productivity VAS, and the Work Limitations Questionnaire (WLQ) was assessed. Relationships between these outcomes and disease activity and patient functional capability were evaluated post hoc. Results At Week 8, change from baseline in EQ-5D-5L index (0.14 vs 0.04), EQ-VAS (17.16 vs 3.69), daily productivity VAS (−2.91 vs −0.71), and WLQ productivity loss score (−2.92 vs −0.78) was greater in the golimumab group versus the placebo group, respectively. At Week 52, change from baseline was similar in the golimumab and placebo-crossover groups (EQ-5D-5L index: 0.17 and 0.15; EQ-VAS: 21.61 and 20.84; daily productivity VAS: −2.89 and −3.31; WLQ productivity loss: −4.49 and −3.28, respectively). HRQoL and productivity were generally associated with disease activity and functional capability, with continued association from Week 8 through Week 52. Conclusion IV golimumab resulted in early and sustained improvements in HRQoL and productivity from Week 8 through 1 year in patients with PsA. HRQoL and productivity improvements were associated with improvements in disease activity and patient functional capability. Key Points• In patients with active psoriatic arthritis (PsA), intravenous (IV) golimumab improved health-related quality of life (HRQoL) and productivity as early as 8 weeks and maintained improvement through 1 year• Improvements in HRQoL and productivity outcomes in patients with PsA treated with IV golimumab were associated with improvements in disease activity and patient functional capability outcomes• IV golimumab is an effective treatment option for PsA that can mitigate the negative effects of the disease on HRQoL and productivity

BMI, disease activity, and health-related quality-of-life in systemic lupus erythematosus

2010 ◽  
Vol 29 (12) ◽  
pp. 1413-1417 ◽  
Author(s):  
Li-Wei Zhu ◽  
Tao Zhang ◽  
Hai-Feng Pan ◽  
Xiang-Pei Li ◽  
Dong-Qing Ye
Keyword(s):  
Quality Of Life ◽  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Health Related Quality ◽  
Systemic Lupus ◽  
Related Quality ◽  
Health Related
Sign in / Sign up

Export Citation Format

Share Document